Downstream Processing Featured Articles

1. Targeting Sugars In The Quest For A Vaccine Against HIV — The Virus That Causes AIDS 8/21/2012

   As a step toward designing the first effective vaccine against HIV, the virus that causes AIDS, scientists are reporting new insights into how a family of rare, highly potent antibodies bind to HIV and neutralize it — stop it from infecting human cells. 

2. Lpath Receives First U.S. Patent For Anti-LPA Antibody, Lpathomab 4/25/2012

   Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, received official notification from the U.S. Patent and Trademark Office (USPTO) that it has been issued a key patent protecting Lpathomab™, a monoclonal antibody against lysophosphatidic acid (LPA).

3. MorphoSys And Heptares Sign Alliance To Develop Antibody Therapeutics Targeting GPCRs 2/13/2013

   MorphoSys AG (Prime Standard Segment, TecDAX) and UK-based Heptares Therapeutics, the leading GPCR drug discovery and development company, have signed an agreement to discover novel antibody therapeutics targeting G protein-coupled receptors (GPCRs), which are membrane proteins involved in a broad range of biological processes and diseases.

4. Novavax Publishes Preclinical Efficacy Study Of Its RSV Protein Nanoparticle Vaccine Candidate 12/3/2012

   Novavax, Inc. (Nasdaq: NVAX) today announced that the journal PLOS ONE (http://dx.plos.org/10.1371/journal.pone.0050852) published data from a preclinical study of its recombinant nanoparticle vaccine candidate against respiratory syncytial virus (RSV), demonstrating efficacy and safety in a well-established animal model.

5. Sunshine Biopharma Initiates IND-Enabling Studies For Its Anticancer Compound, Adva-27a 11/13/2012

   Sunshine Biopharma Inc. (OTCBB: SBFM), a pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has initiated the IND-Enabling studies for Adva-27a, the Company's flagship oncology drug candidate.

6. A Welcome Predictability 10/8/2012

   Synthetic biology is the latest and most advanced phase of genetic engineering, holding great promise for helping to solve some of the world's most intractable problems, including the sustainable production of energy fuels and critical medical drugs, and the safe removal of toxic and radioactive waste from the environment.

7. Abcentra Chief Looks Beyond The Clinical Horizon 9/26/2019

   Why Bert Liang, M.D., Ph.D. obsesses over at-scale manufacturing and regulatory challenges from the outset of clinical trials. 

8. NIH-Funded Researchers Create Next-Generation Alzheimer's Disease Model 4/9/2013

   A new genetically engineered lab rat that has the full array of brain changes associated with Alzheimer’s disease supports the idea that increases in a molecule called beta-amyloid in the brain causes the disease, according to a study, published in the Journal of Neuroscience.

9. Article: How To Choose An Industrial Cation Exchanger For IgG Purification

   Cation-exchange chromatography is the third most used industrial method for antibody purification after anion-exchange and protein A affinity chromatography. It is most commonly used as an intermediate step but continues to attract attention as a capture method. By Pete Gagnon

10. Selecta Biosciences And Sanofi Sign Global Collaboration To Develop Antigen-Specific Immunotherapies For Up To Three Allergy Indications Based On Selecta's Synthetic Vaccine Particle Technology 11/28/2012

    Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company developing a new class of synthetic vaccines and immunotherapies, recently announced that it has entered into a strategic global collaboration with Sanofi to discover highly targeted, antigen-specific immunotherapies for life-threatening allergies.